There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University's College ...
Determining which patients should receive the treatment will still require individual risk-benefit assessments, experts say.
Research by University of Sydney scientists has uncovered a mechanism that may explain why glioblastoma returns after ...
With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...
A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would ...
A new class of life-saving drugs is helping children who once had no hope. But some carry a price tag of millions for a ...
Once the exchange agreements close, Sarepta will have $893.4 million in debt due in 2030 following previous refinancing it announced in August.
Sarepta Therapeutics (NASDAQ:SRPT) leads in genetic therapies, contributing to ongoing discussions surrounding the nasdaq ...
Sarepta Therapeutics (SRPT) has quietly staged a sharp rebound over the past month, even though the longer term chart still looks bruised. That mix of momentum and past damage naturally raises ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback